In patients with myeloid neoplasms and germline predisposition without potential organ dysfunction (i.e., patients with germline mutation in RUNX1, DDX41, CEBPA and so on), no specific complication after HSCT has been reported till date. Here, CEBPA is linked to myeloid neoplasm.